Sign Up for Newsletter
Your Support

Children with cancer and other serious blood disorders depend on red cell and platelet support to complete treatment safely. Since September 18, 2026, Jehovah’s Witnesses have been accepting these components as a matter of individual conscience and decision-making. Everything published so far on the care of children from Jehovah’s Witness families was written before that change. This article summarizes that evidence, explains what it can and cannot tell clinicians today, and outlines a practical, individualized approach for pediatric teams.

Click to download this article.
Key Takeaways
  • Red cells, white cells, platelets, and plasma from donated blood are now matters of individual conscience for Jehovah’s Witnesses; whole-blood transfusion remains outside current guidance [1][2].
  • All published pediatric data, including the 2026 Blood “How I Treat” review, were collected or written before the September 2026 change [3].
  • Even before 2026, family preferences varied: 60% of guardians in one pediatric oncology cohort accepted blood products when prescribed [4], and among 196 children receiving bloodless care at one center, 6.1% received an allogeneic component, and none required a court order [5].
  • Pediatric thresholds are restrictive: red cells below 7 g/dL for stable critically ill children, and prophylactic platelets below 10 × 10⁹/L during chemotherapy and 20 × 10⁹/L before lumbar puncture [6][7].
  • Early, specific, component-by-component conversations with parents and, as appropriate, with the child or adolescent, documented and revisited as treatment changes, remain the foundation of care.

A note on the evidence

Every study, case report, and review cited in this article predates the guidance issued by the Governing Body of Jehovah’s Witnesses on September 18, 2026. The cohorts described here were treated when red cells, platelets, plasma, and white cells were excluded for members, and the published outcomes reflect that setting. The most recent review on the subject, by Weaver, Takemoto, and Johnson in Blood, carries a publisher’s note stating that the guidance on primary blood components was revised after the manuscript was accepted, and that the article will be updated before final publication [3].

These data remain useful. They show how varied family decisions already were, which transfusion-sparing measures work in children, and how teams and families have reached agreement. They do not show how families will decide under the new guidance; no data on that question exist yet. Two 2026 reviews cited here, on perioperative blood management and on English court judgments, were also published before September 18, 2026 [8][9].

Why component support matters in childhood cancer

There has been a distinct shift toward reducing transfusion use—not only among Jehovah’s Witness patients, but across clinical practice worldwide—as evidence continues to show that avoiding unnecessary transfusions may be associated with better outcomes. This shift is particularly relevant in pediatric oncology, where most curative regimens are myelosuppressive and transfusion support remains an important part of delivering treatment safely [4].

Your Support
Sign Up for Newsletter

Children with acute lymphoblastic leukemia (ALL), for example, undergo repeated lumbar punctures for intrathecal therapy, often during periods of chemotherapy-induced thrombocytopenia. Emerging evidence indicates that these procedures can be performed safely in children with mild-to-moderate chemotherapy-induced thrombocytopenia without routine prophylactic platelet transfusion. Nevertheless, prophylactic platelet transfusions remain commonly used at defined thresholds, typically when platelet counts fall below 10 × 10⁹/L [10].

Advertisement #3

Current guidelines set restrictive targets. The 2023 Association for the Advancement of Blood & Biotherapies (AABB) guideline recommends considering red cell transfusion below 7 g/dL in hemodynamically stable critically ill children without a hemoglobinopathy, cyanotic heart disease, or severe hypoxemia [6].

The 2025 AABB and the International Collaboration for Transfusion Medicine Guidelines (ICTMG) platelet guideline recommends prophylactic platelets below 10 × 10⁹/L during chemotherapy or allogeneic transplant, below 20 × 10⁹/L before lumbar puncture, and below 25 × 10⁹/L in neonates with consumptive thrombocytopenia without major bleeding [7]. For hemodynamically stable critically ill children with oncologic diagnoses or undergoing hematopoietic stem cell transplantation, the Pediatric Critical Care Transfusion and Anemia Expertise Initiative (TAXI) suggests a red cell threshold of 7 to 8 g/dL [11]. These thresholds already reflect a long effort to give children no more blood than they need.

What changed in 2026

On March 20, 2026, the Governing Body of Jehovah’s Witnesses made the collection, storage, and reinfusion of a member’s own blood a personal decision [12]. On September 18, 2026, it did the same for red cells, white cells, platelets, and plasma from donated blood, while keeping transfusion of donated whole blood outside current guidance [1][2]. Members are asked to make these decisions through prayer and study [1]. In pediatric care, parents and adolescents, as they mature, may now accept one, several, all, or none of the four components.

Individualized care for children and adolescents

Caring for children and adolescents with hematologic or oncologic disorders whose families identify as Jehovah’s Witnesses requires careful attention to clinical management, informed consent, family preferences, and, when necessary, ethical and legal considerations. Historically, clinicians have often approached these cases expecting that blood transfusion would be declined.

The literature, however, shows that individual decisions about blood products vary and should not be assumed based on religious affiliation alone [3]. Weaver and colleagues describe preferences shaped by individual conscience, cultural context, and interpretation of religious guidance, and they describe clinical situations in which these beliefs, the child’s developing autonomy, and the medical circumstances intersect [3].

For pediatric hematology-oncology teams, the September 2026 guidance reinforces the importance of discussing transfusion preferences directly with each patient and family. Rather than assuming what a family will or will not accept, clinicians should establish specific preferences before treatment begins whenever circumstances permit. That discussion should cover each blood component, blood fractions, and procedures involving the patient’s own blood. Document preferences clearly in the medical record and revisit them when clinical circumstances change. For children and adolescents, these discussions also require attention to age, maturity, the child’s participation in decision-making, and the responsibilities of parents or other legal decision-makers [3].

What the pediatric evidence shows

Preferences were already heterogeneous. At Children’s Healthcare of Atlanta, investigators reviewed 35 patients aged 0 to 21 years with cancer, treated between 2006 and 2020, whose records indicated a risk of transfusion being declined [4]. Of these, 89% had guardians who identified as Jehovah’s Witnesses, and only 40% of guardians actively declined transfusion; 60% accepted blood products when they were prescribed for oncology care [4]. Overall, 22 of the 35 patients received blood products. Legal intervention preceded transfusion in 36.4% of those transfused, and 4 of 22 guardians initially declined but later consented; the median hemoglobin before the first transfusion was 6.7 g/dL [4]. Ten patients received erythropoietin without thromboembolic or cardiovascular events, and five received aminocaproic acid [4]. The authors called for systematic, transfusion-sparing management guidelines that honor family preferences while protecting cancer outcomes [4].

Bloodless care can be delivered safely in many children. At Johns Hopkins, 196 inpatients younger than 18 years requested bloodless care between 2012 and 2016 [5]. Compared with more than 37,000 children receiving standard care, transfusion rates were similar (6.1% vs 9.1%), composite morbidity was lower (2.6% vs 6.2%), and no child in the bloodless cohort died [5]. None of the 12 transfusions given was administered under a court order, and the authors concluded that a collaborative, patient-centered approach can safely limit transfusion in children, while noting that larger studies are needed [5].

Standard protocols with fewer transfusions. At two German pediatric cancer centers, 14 children from Witness families received 21 treatment courses according to cooperative-group protocols over 16 years [12]. Supportive measures included iron, erythropoietin, interleukin-11, granulocyte colony-stimulating factor (G-CSF), and autologous or allogeneic stem cell rescue. Compared with matched controls, these children received 39.1% fewer red cell and 37.5% fewer platelet transfusions during primary therapy, and 9 of 14 were alive 16 to 195 months after treatment [13]. The authors concluded that children from Jehovah’s Witness families can be treated much like other patients, and that a restrictive transfusion policy, broad use of supportive care, and continuous collaboration with the Hospital Liaison Committee (HLC: see below) can create a setting in which court orders may not be necessary [13].

Expert guidance from three clinical scenarios. The 2026 Blood review works through three cases [3]. The first, an adolescent with relapsed Hodgkin lymphoma considering autologous hematopoietic cell transplantation, addresses the balance between emerging autonomy, deeply held beliefs, and standard-of-care practice. The second, an infant with severe aplastic anemia, addresses disagreement within a family, surrogacy and delegation of consent, and the circumstances in which legal intervention may be needed to protect the child. The third, a child receiving chronic transfusions, shows that decisions are made repeatedly over time rather than once. The authors recommend assessing how deeply and personally a family, and the young patient, hold their beliefs, and they emphasize ethical humility, data-driven assessment, and interdisciplinary collaboration [3].

Transfusion-sparing care in children

Weaver and colleagues group transfusion-sparing strategies into three pillars: mitigating anemia, preventing bleeding, and conserving blood [3]. The Johns Hopkins bloodless program describes the components in detail [14]. Blood loss from laboratory testing is reduced with pediatric phlebotomy tubes and conservative testing; anemia is treated with erythropoiesis-stimulating agents (ESAs), together with iron, folate, and vitamin B12 when indicated; and surgical patients benefit from preoperative treatment of anemia, autologous blood salvage, and procedures that minimize blood loss [14]. Microtainer tubes hold about 0.5 mL, roughly 95% less than standard tubes, a meaningful difference for a small child whose total blood volume is limited [15].

In adults, a risk-adjusted, propensity-matched analysis of all hospitalized patients who declined transfusion at the same center found that bloodless management was not an independent predictor of adverse outcomes; overall mortality was lower in the bloodless group, and discharge hemoglobin was similar [14]. The authors noted that no prospective studies yet guide management [14].

A 2026 German review of perioperative blood management in Jehovah’s Witness patients describes the same framework for planned surgery: timely, structured treatment of anemia, viscoelastic point-of-care coagulation testing, and selective use of autologous procedures such as mechanical autotransfusion (cell salvage) [8]. The authors also present a structured consent questionnaire, developed at the University of Bonn, which records patient decisions procedure by procedure and is intended to reduce uncertainty in the team [8].

Less myelosuppressive therapy. Newer agents can sometimes reduce the marrow toxicity that drives transfusion needs. In a UK audit of 60 children and young people with B-precursor ALL treated with blinatumomab (Blincyto; Amgen) in place of parts of post-remission chemotherapy, the drug was given mainly for prior chemotherapy toxicity or comorbidities, and in one case to minimize transfusion requirements in a patient from a Jehovah’s Witness family [16]. Of 50 patients with measurable residual disease before treatment, 48 (96%) reached levels below 0.01%; one grade 3 neurotoxicity event and no grade 2–4 cytokine release syndrome were reported [16]. These are short-term results from a meeting abstract, and the authors noted that longer follow-up is needed [16].

For families who now accept some components, these strategies lower how often those components are needed. For families who continue to decline them, they remain the principal means of support.

Hematologic malignancies and solid tumors

Blood management priorities differ between the two main groups of childhood cancers. In leukemia and lymphoma, the marrow is often involved, and cytopenias follow repeated cycles of myelosuppressive therapy; the main tools are restrictive thresholds, limited phlebotomy, and pharmacologic support of erythropoiesis and hemostasis [4][7][11]. In solid tumors such as nephroblastoma (Wilms tumor) and neuroblastoma, marrow function is often normal at diagnosis, and the largest single blood loss usually occurs during resection; preoperative treatment of anemia, autologous techniques, and meticulous hemostasis are central [8][14].

Retrospective data from pediatric surgical oncology further support limiting transfusion where safely possible. Among 360 children who underwent solid tumor resection at one US center between 2002 and 2013, 54% received red cells within 30 days of surgery; after adjustment for stage, tumor location, preoperative chemotherapy, and nadir hemoglobin, transfusion was associated with more postoperative infections, a shorter disease-free interval, and more recurrences [17].

In a European multicenter study of 65 children undergoing nephroblastoma surgery, intraoperative red cell transfusion was associated with shorter recurrence-free survival, without a difference in overall survival [18]. Both studies are observational; they show associations and do not establish that transfusion causes recurrence.

Neonates and infants

The smallest patients have the fewest alternatives. A 2016 case report described an infant born at 23 weeks’ gestation to parents who requested full intensive care without transfusion [19]. The clinical team obtained a court order, erythropoietin was started on the first day of life, and blood draws were minimized; the infant later received five red cell transfusions and one transfusion each of plasma and platelets, developed bilateral severe intraventricular hemorrhage, and died after a decision to withdraw life-sustaining treatment [18]. The authors concluded that care at the border of viability currently requires red cell transfusion, and that distress for parents and staff can be reduced through early, clear, and consistent communication [19]. The infant with severe aplastic anemia discussed by Weaver and colleagues illustrates a similar point in hematology: when marrow failure is complete, the room for transfusion-sparing measures is narrow [3].

Beyond Oncology: Sickle cell disease

Sickle cell disease (SCD), an inherited blood disorder characterized by sickled red blood cells and chronic anemia, has historically relied on red cell transfusion for many acute complications. A 2024 survey distributed through the Witness medical information network received 28 responses from individuals with SCD [20]. Of those who had not sought care for a severe pain crisis, 29% cited the need or recommendation for transfusion, while 54% cited fear of being labeled as drug-seeking and 54% cited long waiting times; these barriers mirror those reported in the wider US SCD population [20].

Most respondents reported regular use of disease-modifying therapy, most often hydroxyurea (68%) [19]. The sample was small, and the survey predates the 2026 guidance.

Families, adolescents, and shared decision-making

Pediatric oncologists have described what helps when families and clinicians start from different positions. In qualitative interviews with US pediatric oncologists, approaches clustered around three themes: communication logistics, establishing trust, and negotiation and compromise [21]. Most participants relied on ethics consultation and wanted more structured preparation and guidance [21].

Psychologists working in medical settings can support these conversations. A review written for that profession examines the values of the Witness community, the origin of its position on blood, how medical and legal professionals have approached disagreement, and the ethical standards that guide psychologists, and it argues for a fuller understanding of harm as families experience it [22].

The 2026 guidance gives these conversations more room. A family that previously declined all components may now consider platelets for a lumbar puncture or red cells during induction, and each decision can be discussed on its own terms. Adolescents deserve a role in these discussions appropriate to their maturity, and their views can be explored privately as well as with their parents [3].

When agreement is difficult

In the United States, the legal framework for minors differs from that for adults. Courts have long distinguished an adult’s right to decline treatment from a parent’s authority to decline life-sustaining treatment for a child. The principle is usually traced to Prince v. Massachusetts (1944), a US Supreme Court case on child labor laws, not medicine, in which the Court held that parental and religious liberty can be limited when a child’s welfare is at stake [23]. Pediatric case literature has relied on this principle [19]. The same literature notes that consent is usually sought from a court except in an emergency in which time is of the essence, and that whether an older minor can decide for themselves is judged case by case, based on the ability to understand the treatment, its alternatives, and their consequences [19].

Other jurisdictions take comparable approaches. A 2026 review of 19 English court judgments involving children from Witness families found two broad groups, infants and capable teenagers, and showed how judicial thinking has developed over time [9]. The authors recommended concentrating clinical judgment on compulsory transfusion in pediatric hematology-oncology centers and avoiding rolling or open-ended authority to transfuse [9].

In one recent English case, a 17-year-old Witness scheduled for ureteric surgery with a small risk of major bleeding was found competent to decline blood products, and the court declined the hospital’s request for authority to transfuse [24][25]. His written advance decision, made before age 18, had no statutory force under the Mental Capacity Act 2005, but the court respected his contemporaneous, competent decision [25].

In Germany, a 2026 review notes that advance directives bind clinicians caring for capable adults, while in emergencies involving children, the child’s welfare takes priority [8]. Legal requirements differ between jurisdictions, and institutions should involve their ethics and legal teams early when agreement is uncertain.

In interviews with 30 pediatric oncologists about treatment refusal, nonadherence, and abandonment in general, most who engaged the legal system did so first through child protective services; a court order without a prior report was sought in a single case, involving a family that declined transfusion but accepted the rest of cancer treatment [26]. Clinicians weighed the child’s age, the efficacy and burden of treatment, prognosis, family resources and social context, and the importance of preserving the therapeutic relationship, and the authors called for closer dialogue between clinicians, child protective services, and legal professionals [26]. Weaver and colleagues also address ethical thresholds for intervention, the use of preemptive court orders, and communication practices that preserve trust and limit moral distress [3].

Collaboration often makes formal steps unnecessary. In one case report, a 15-year-old girl with a large ovarian mass and massive hemoperitoneum, whose parents declined blood products, was transferred after discussion with the patient, family, and consultants to a hospital with a surgical blood conservation program and underwent surgery without transfusion; her surgeons reserved the legal right to transfuse if an emergency arose [27]. In the Johns Hopkins cohort, no court order was needed for any of the 196 children who requested bloodless care [5].

A bridge between patients and clinicians

Hospital Liaison Committees (HLCs) for Jehovah’s Witnesses can support both clinical teams and families. Some 2,000 committees in more than 110 countries, staffed by trained volunteer ministers, offer free services on request, available around the clock [28]. They brief hospital teams and help arrange care plans tailored to each patient, provide clinicians with specialty-specific clinical strategies and information on managing anemia and avoiding transfusion, arrange presentations for hospital staff, and help locate experienced clinicians and facilities [28][29]. In this approach, the clinical team retains the medical assessment, and the family, and increasingly the adolescent patient, retains the decision.

Practical steps for pediatric teams
  • At diagnosis, ask parents, and the patient when age-appropriate, about each component separately: red cells, platelets, plasma, and white cells, along with fractions and the use of the child’s own blood [1][2].
  • Review any advance directive or chart flag recorded before September 18, 2026, and update it to reflect current wishes.
  • Anticipate high-need periods such as induction, lumbar punctures, transplantation, and surgery, and revisit decisions before each.
  • Build a transfusion-sparing plan for every child: limit phlebotomy, mitigate anemia, and provide bleeding prophylaxis [3][14].
  • Involve ethics consultation, psychology, and social work early when views differ, and invite the local Hospital Liaison Committee if the family wishes [21] [22][28].
  • Ensure that oncology, anesthesia, surgery, transfusion medicine, and nursing teams share one current record of the family’s decisions.
What remains to be learned

All published pediatric series and reviews predate the September 2026 guidance [3][4][5]. Future studies will need to record which components each family accepted, how adolescents took part in decisions, and how component acceptance relates to treatment delivery and outcomes. The updated version of the Blood review is expected to address the new guidance directly [3].

Conclusion

For children with cancer and other serious blood disorders, the 2026 guidance means that families who choose red cells, platelets, or plasma can receive guideline-based support, while families who decline them can continue to rely on established transfusion-sparing care. The available evidence, all gathered before the change, points in one direction: early, specific, and respectful conversations, shared across the whole care team, allow most children to be treated safely and in keeping with their family’s values.


Highlights of Prescribing Information

Use transfusion-sparing agents, including iron preparations, ESAs, and antifibrinolytics, in children according to current prescribing information, weight-based dosing, and institutional protocols. ESAs carry boxed warnings on mortality, cardiovascular and thromboembolic events, and tumor progression or shortened survival in patients with cancer. Blinatumomab carries a boxed warning for cytokine release syndrome and neurological toxicities.

Drugs mentioned in this article
  • Blinatumomab (Blincyto®; Amgen) [Prescribing Information]
  • Epoetin alfa (Epogen®; Amgen)[Prescribing Information]
  • Epoetin alfa (Procrit®; Janssen)[Prescribing Information]
  • Hydroxyurea (Droxia®; Bristol Myers Squibb / Siklos®; Medunik USA; generics also available) [Medication Guide]
  • Aminocaproic acid (Amicar®; generics also available; multiple manufacturers) [Prescribing Information]
  • Filgrastim (G-CSF) (Neupogen®; Amgen; biosimilars also available) [Prescribing Information]
  • Oprelvekin (interleukin-11) (Neumega®; Pfizer/Wyeth (no longer marketed in the United States)
  • Iron preparations, folic acid, vitamin B12 (multiple manufacturers)
References

[1] Smith P. Jehovah’s Witnesses allow blood-derived products but keep ban on whole-blood transfusions. Associated Press. September 18, 2026. Online. Last accessed October 1, 2026.
[2] Jehovah’s Witnesses. 2026 Governing Body Update #6. JW.ORG. September 18, 2026. Online. Last accessed October 1, 2026.
[3] Weaver MS, Takemoto C, Johnson LM. How I Treat Pediatric Hematology-Oncology Patients from Families Identifying as Jehovah’s Witnesses. Blood. 2026 Sep 4:blood.2026033728. doi: 10.1182/blood.2026033728. Epub ahead of print. PMID: 42696604.
[4] Stevenson J, DeGroote NP, Keller F, Brock KE, Bergsagel DJ, Miller TP, Cornwell P, Fasano R, Chonat S, Castellino SM. Characteristics and outcomes of pediatric oncology patients at risk for guardians declining transfusion of blood components. Cancer Rep (Hoboken). 2023 Jan;6(1):e1665. doi: 10.1002/cnr2.1665. Epub 2022 Jul 6. PMID: 35792092; PMCID: PMC9875642.
[5] Lo BD, Pippa A, Sherd I, Scott AV, Thomas AJ, Hendricks EA, Ness PM, Chaturvedi S, Resar LMS, Frank SM. Clinical outcomes, blood utilization, and ethical considerations for pediatric patients in a bloodless medicine and surgery program. Anesth Analg. 2024;138(2):465-474. PMID: 38175737.
[6] Carson JL, Stanworth SJ, Guyatt G, et al. Red blood cell transfusion: 2023 AABB international guidelines. JAMA. 2023;330(19):1892-1902. doi: 10.1001/jama.2023.12914. PMID: 37824153.
[7] Metcalf RA, et al. Platelet transfusion: 2025 AABB and ICTMG international clinical practice guidelines. JAMA. 2025;334(7):606-617. doi: 10.1001/jama.2025.7529. PMID: 40440268.
[8] Piekarski F, Menzenbach J, Hilbert T, Hersch J, Schindler E, Coburn M, Grabert J. Perioperative blood management in Jehovah’s Witnesses. Anaesthesiologie. Published online May 4, 2026. doi: 10.1007/s00101-026-01683-1. PMID: 42081097.
[9] Wheeler R, Formstone M. Children of Jehovah’s Witnesses: a review of judicial responses to the refusal of blood transfusion. Arch Dis Child. 2026;111(8):682-685. doi: 10.1136/archdischild-2025-329204. PMID: 41443962.
[10] Howard SC, Gajjar A, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, Harrison PL, de Armendi A, Dahl GV, Pui CH. Safety of lumbar puncture for children with acute lymphoblastic leukemia and thrombocytopenia. JAMA. 2000 Nov 1;284(17):2222-4. doi: 10.1001/jama.284.17.2222. PMID: 11056594.
[11] Steiner ME, Zantek ND, Stanworth SJ, Parker RI, Valentine SL, Lehmann LE, Josephson CD, Bateman ST, Luban NLC. Recommendations on RBC transfusion support in children with hematologic and oncologic diagnoses from the Pediatric Critical Care Transfusion and Anemia Expertise Initiative. Pediatr Crit Care Med. 2018;19(9S Suppl 1):S149-S156. doi: 10.1097/PCC.0000000000001610. PMID: 30161070; PMCID: PMC6126910.
[12] Jehovah’s Witnesses to permit autologous blood transfusion. AABB News. March 24, 2026. Online.
[13] Tenenbaum T, Hasan C, Kramm CM, Janssen G, Laws HJ, Wessalowski R, Bode U, Göbel U. Oncological management of pediatric cancer patients belonging to Jehovah’s Witnesses: a two-institutional experience report. Onkologie. 2004;27(2):131-137. doi: 10.1159/000076901. PMID: 15138344.
[14] Resar LM, Frank SM. Bloodless medicine: what to do when you can’t transfuse. Hematology Am Soc Hematol Educ Program. 2014;2014(1):553-558. doi: 10.1182/asheducation-2014.1.553. PMID: 25696910.
[15] Johns Hopkins Medicine. Bloodless medicine proves successful. February 2018. Online.
[16] Hodder A, Mishra AK, Baird S, et al. Blinatumomab as toxicity sparing first line treatment of children and young persons with B-precursor acute lymphoblastic leukaemia (B-ALL). Blood. 2022;140(Suppl 1):8987-8988 (meeting abstract). doi: 10.1182/blood-2022-162475.
[17] Acker SN, Nolan MM, Prendergast C, Lyttle B, Fares S, Bensard DD, Partrick DA. Blood Transfusion is Associated With Adverse Outcomes in Pediatric Solid Tumor Oncology Patients Following Tumor Resection. J Pediatr Hematol Oncol. 2023 Apr 1;45(3):137-142. doi: 10.1097/MPH.0000000000002530. Epub 2022 Aug 22. PMID: 36031190.
[18] Müller SD, et al. Association between intraoperative blood transfusion, regional anesthesia and outcome after pediatric tumor surgery for nephroblastoma. Cancers (Basel). 2022;14(22):5585. doi: 10.3390/cancers14225585. PMCID: PMC9688304. [Full author list and PMID to be confirmed]
[19] Sauer CW, Marc-Aurele KL. Attempting to honor beliefs of Jehovah’s Witnesses at the edge of viability in an infant born at 23 weeks’ gestational age. Am J Case Rep. 2016;17:375-378. doi: 10.12659/AJCR.898002. PMID: 27255268; PMCID: PMC4917075.
[20] Tabiti BF, Hsu LL. Do Jehovah’s Witnesses with sickle cell disease avoid the healthcare system? Blood. 2024;144(Suppl 1):3630 (meeting abstract). doi: 10.1182/blood-2024-208683.
[21] Caruso Brown AE, Beskow LM, Benedetti DJ. Approaches to Addressing Pediatric Cancer Treatment Refusal Beyond Legal Action. Pediatr Blood Cancer. 2025 Oct;72(10):e31949. doi: 10.1002/pbc.31949. Epub 2025 Aug 1. PMID: 40751325.
[22] Hoffman A. Jehovah’s Witness parents’ refusal of blood transfusions: ethical considerations for psychologists. J Health Psychol. 2016;21(8):1556-1565. doi: 10.1177/1359105314558896. PMID: 25476572.
[23] Prince v. Massachusetts, 321 U.S. 158 (1944). Online. Last accessed on October 1, 2026.
[24] Re J (Blood Transfusion: Older Child: Jehovah’s Witnesses) [2024] EWHC 1034 (Fam). High Court of England and Wales, Family Division. April 15, 2024. Online. Last accessed October 1, 2026.
[25] Andoh B. Right to refuse treatment upheld while advance directive failed. Medico-Legal Journal. 2025. doi: 10.1177/00258172241280435.
[26] Caruso Brown AE, Beskow LM, Benedetti DJ. Legal Involvement in Pediatric Cancer Treatment Refusal: A Qualitative Study. Pediatrics. 2024 Nov 1;154(5):e2024066180. doi: 10.1542/peds.2024-066180. PMID: 39415696.
[27] Brezina PR, Moskop JC. Urgent medical decision making regarding a Jehovah’s Witness minor: a case report and discussion. N C Med J. 2007;68(5):312-316. PMID: 18183749.
[28] Jehovah’s Witnesses. Hospital Liaison Committees for Jehovah’s Witnesses. JW.ORG. Online.
[29] Jehovah’s Witnesses. Evidence-based medical information for avoidance of blood transfusion. JW.ORG. Online. Last accessed October 1, 2026.

This article is intended for healthcare professionals. It does not replace clinical judgment, institutional policy, applicable law, or individualized informed consent. All studies cited were conducted or written before the September 18, 2026, guidance.

Featured image: © 2026 CH Compassionate Care in the Pediatric Ward. Used with permission.


DOI: 10.14229/onco.2026.08.10.002

 

Sign Up for Newsletter
Your Support

Advertisement #5